New Delhi, June 13 -- The Serum Institute of India (SII), the world's largest vaccine manufacturer and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research entity, have entered into a partnership with an aim to accelerate the development of a monoclonal antibody treatment for dengue fever.
The initiative specifically targets low- and middle-income countries (LMICs), where dengue is endemic and health systems are often under strain during outbreaks, said a joint statement here from the organisations.
Despite the rising global burden of dengue - with an estimated 3.9 billion people at risk and cases more than doubling annually since 2021 - there is currently no specific treatment available. The new monoclonal antibo...